A step forward in the fight against rare pediatric brain tumors – AIEOP
AIEOP (Italian Association of Pediatric Hematology and Oncology) shared a post on LinkedIn:
“New SIOPE ATRT01 study: a step forward in the fight against rare pediatric brain tumors.
In December 2024, the new SIOPE ATRT01 protocol, an international phase III trial dedicated to children with atypical teratoid rhabdoid tumors (ATRT), started in Italy.
What is ATRT?
It is a very rare brain tumor, which mainly affects very young children, with low survival rates despite intensive treatments.
Objectives of the study:
Compare two different therapeutic approaches:
- Standard radiotherapy (RT) combined with conventional chemotherapy.
- High-dose chemotherapy (HDCT) with autologous reinfusion of stem cells.
The aim: Increase the chances of recovery by reducing side effects, especially neurocognitive ones.
The 3 arms of the trial:
Arm A: Includes a randomized study for children between 12 and 35 months, comparing conventional RT (combined with 12 cycles of chemotherapy) with three cycles of HDCT. HDCT, the experimental arm of the study, involves three cycles of high-dose chemotherapy with Carboplatin and Thiotepa, with subsequent autologous reinfusion of stem cells.
Arm B: Includes children under 12 months, who will be treated exclusively with HDCT.
Arm C: It is aimed at children over 35 months, who will receive RT combined with 12 cycles of conventional chemotherapy.
The study is sponsored by AIEOP and coordinated in Italy by Dr. Angela Mastronuzzi, of the Bambino Gesù Children’s Hospital in Rome.
The study will soon be opened in other Italian centers (Bologna, Turin, Milan, Naples, Padua).
For further information email: [email protected].”
More posts featuring AIEOP.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023